Thursday, November 20, 2008

Brain Tumor News Blast!

This news brief is bought to you by:
The Musella Foundation For Brain Tumor Research & Information.

To unsubscribe, go to:

To view past stories - or submit a story / press release, go to:

===================================================================== :Celprogen Introduces an in vivo Model for Human Brain Cancer (Human Glioblastoma GBM) for Drug Discovery Applications

===================================================================== : Phase I/II Trial Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177.

===================================================================== : Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme.

===================================================================== : Pediatric glioblastomas: A histopathological and molecular genetic study.

===================================================================== :Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.

===================================================================== : Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab (Avastin) plus irinotecan (CPT-11).

===================================================================== :abCorp developing new brain cancer test

Post a Comment
Related Posts Plugin for WordPress, Blogger...

Popular Posts